Table 4.
Multivariate predictors of MYCN status in 2,585 patients with stage 4 neuroblastoma.1
| Predictor variable2 (Unfavorable category shown / Favorable category is reference) |
Number of patients with unfavorable variable / Number of patients with available data |
Odds Ratio
(95% CI) |
P-value |
|---|---|---|---|
| Chromosome 1p LOH Present |
263 / 650 | 8.6 (5.4–14.0) |
<0.001 |
| LDH > 587 (U/L) | 1028 / 1504 | 6.8 (4.7–9.8) |
<0.001 |
| Chromosome 11q Aberration Absent |
151 / 379 | 6.1 (2.7–13.9) |
<0.001 |
| High MKI | 216 / 869 | 4.8 (3.1–7.5) |
<0.001 |
| Non-thoracic Primary Site |
2300 / 2508 | 3.1 (1.8–5.6) |
<0.001 |
| Lung Metastasis | 78 / 2270 | 2.4 (1.4–4.1) |
0.001 |
| No Skin Metastasis |
2240 / 2305 | 2.1 (1.0–4.4) |
0.05 |
| Diploid or Hypodiploid |
489 / 1166 | 1.8 (1.3–2.5) |
<0.001 |
| Adrenal Primary Site |
1450 / 2508 | 1.6 (1.2–2.0) |
0.001 |
1
At least one known metastatic site specified in the INRG database.
2
Variables tested in the model and found non-significant were: age; ferritin level; grade of differentiation; aberration at 11q; gain of 17q; pooled segmental chromosomal aberrations; and metastasis to bone, bone marrow, distant lymph node, liver, and central nervous system.